Jeffrey Jones, MD

Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment. Jones says one option is to begin salvage treatment with either idelalisib or ibrutinib after one of the two treatment options fails. Utilizing the treatment option not initially chosen has resulted in about a 50% response rate.

Videos

Jeffrey Jones, MD, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment.

Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLL

Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL). Jones says both idelalisib and ibrutinib have been highly effective in the majority of relapsed/refractory CLL.

Jones says that while idelalisib and ibrutinib have been effective overall, there is a small group of patients who cannot receieve the treatment. He says that a different option for patients who cannot undergo those treatments are BCL-2 inhibitors like venetoclax. He adds that in a recent study, venetoclax has proven to be effective in the patient population with CLL who cannot receieve idelalisib and ibrutinib due to toxiticies or high-risk genetic features.

Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).

Jeffrey Jones, MD | Authors

Articles

Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLL

Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLL